

## 2022 Independent Medical Education Call for Grant Notification

**Issue Date: March 3, 2022**

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

**Purpose:** As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

**Notification:** Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

### Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech’s department of Independent Medical Education. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

### Instructions

|                      |   |
|----------------------|---|
| Eligibility Criteria | <ul style="list-style-type: none"> <li>● U.S. based education provider</li> <li>● Registered account in gFRS</li> <li>● Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)</li> </ul> |
| Geographical Scope   | <ul style="list-style-type: none"> <li>● Educational initiatives must be U.S.-based only</li> </ul>   |

| Submission Directions | Application Process   | Deadlines      |
|-----------------------|---|----------------|
| Step 1                | Providers who meet the eligibility criteria and are interested in submitting a response to this CGN have <u>6 weeks</u> to submit full grant application(s) online through <a href="http://funding.gene.com">funding.gene.com</a> (gFRS). | April 14, 2022 |
| Step 2                | Grant decisions will be communicated to the accredited educational provider through gFRS.   | April 21, 2022 |

**Additional Considerations**

Provider(s) who are awarded grants are encouraged to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

**Currently Available CGN Focus Area:**

| Focus   | Opportunity  |
|---|--|
| <p><b>Therapeutic Area:</b><br/>Neurology</p> <p><b>Learning Audience:</b><br/>Neurologists</p> <p>Neuromuscular Specialists</p> <p>Adult Patients with SMA</p> <p>Physical Therapists</p> <p>Nurse Practitioners</p> <p>Physician’s Assistants</p> <p>Multidisciplinary Teams</p> <p><b>Support Available:</b><br/>Up to \$250,000</p> <p>Knowledge- and Competence-based National and Regional Education<br/><i>(Understanding &amp; addressing national or local gaps and emerging data)</i></p> | <p>Adults (&gt;18 yrs.) comprise more than 25% of patients with spinal muscular atrophy (SMA) globally, but the differences in treatment approach focus, therapeutic goals, clinical issues, and psychosocial needs from that of pediatric patients with SMA are not often recognized by healthcare providers.</p> <p>Over the past few years, new treatment options have become available, and, consequently, healthcare providers need education on the benefits and risks for adults with SMA, as well as how to better engage adult patients to improve their care and treatment outcomes.</p> <p>References:</p> <ol style="list-style-type: none"> <li>1. Mazzella A, Curry M, Belter L, Crus R, Jarecki J. “I have SMA, SMA doesn’t have me”: a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA. <i>Orphanet J Rare Dis.</i> 2021;16(1):96</li> <li>2. Verhaart I, Robertson A, Leary R, McMacken G, Konig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. <i>J Neurol.</i> 2017;264(7):1465–73</li> <li>3. Walter MC, et al. Improving care and empowering adults living with SMA: A call to action in the treatment era. <i>Journal of Neuromuscular Diseases.</i> 2021;8:543-551</li> <li>4. Wan HWY, Carey KA, D’Silva A, Vucic S, Kiernan MC, Kasparian NA, Farrar MA. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. <i>Orphanet Journal of Rare Diseases.</i> 2020 15:70</li> </ol> |